Calton & Associates Inc. purchased a new stake in shares of UnitedHealth Group Inc (NYSE:UNH) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,738 shares of the healthcare conglomerate’s stock, valued at approximately $1,406,000.
A number of other institutional investors have also added to or reduced their stakes in the stock. Exane Derivatives increased its position in UnitedHealth Group by 15,333.3% during the fourth quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock valued at $102,000 after acquiring an additional 460 shares during the last quarter. Bruderman Asset Management LLC bought a new position in UnitedHealth Group during the second quarter valued at $114,000. Acrospire Investment Management LLC increased its position in UnitedHealth Group by 130.7% during the second quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock valued at $131,000 after acquiring an additional 400 shares during the last quarter. Baystate Wealth Management LLC increased its position in UnitedHealth Group by 64.9% during the fourth quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock valued at $186,000 after acquiring an additional 300 shares during the last quarter. Finally, Legacy Advisors LLC increased its position in UnitedHealth Group by 546.0% during the fourth quarter. Legacy Advisors LLC now owns 801 shares of the healthcare conglomerate’s stock valued at $176,000 after acquiring an additional 677 shares during the last quarter. 86.83% of the stock is currently owned by institutional investors.
A number of research analysts have weighed in on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $280.00 price objective on shares of UnitedHealth Group in a research report on Thursday, March 8th. Barclays assumed coverage on shares of UnitedHealth Group in a research report on Thursday, March 8th. They set an “overweight” rating and a $265.00 price objective on the stock. Credit Suisse Group reiterated a “buy” rating on shares of UnitedHealth Group in a research report on Friday, March 9th. Citigroup boosted their price objective on shares of UnitedHealth Group from $235.00 to $268.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Finally, Oppenheimer boosted their price objective on shares of UnitedHealth Group from $215.00 to $225.00 and gave the company an “outperform” rating in a research report on Wednesday, November 29th. Two investment analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $245.14.
In other UnitedHealth Group news, Director Richard T. Burke sold 10,400 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $229.87, for a total transaction of $2,390,648.00. Following the transaction, the director now directly owns 1,781,657 shares in the company, valued at approximately $409,549,494.59. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kenneth Irwin Shine sold 198 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $242.55, for a total transaction of $48,024.90. Following the transaction, the director now owns 1,790,567 shares in the company, valued at $434,302,025.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,598 shares of company stock worth $7,280,073. 0.89% of the stock is owned by company insiders.
UnitedHealth Group Inc (NYSE UNH) opened at $227.86 on Friday. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.58. UnitedHealth Group Inc has a 1-year low of $162.74 and a 1-year high of $250.79. The stock has a market cap of $222,059.28, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.34 and a beta of 0.74.
UnitedHealth Group (NYSE:UNH) last issued its earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.09. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.29%. The company had revenue of $52.06 billion for the quarter, compared to analysts’ expectations of $51.57 billion. During the same period in the prior year, the business earned $2.11 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. equities analysts anticipate that UnitedHealth Group Inc will post 12.51 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 20th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.32%. The ex-dividend date is Thursday, March 8th. UnitedHealth Group’s payout ratio is 28.01%.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.